Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Amlodipine

Preparation Calculator

Amlodipine

Calcium channel blocker (DHP, vascular-predominant)

AdultCCBDHPHTNAngina

Indication

HTN β€’ chronic angina

At a glance

INDICATIONS (CORE USE)

Chronic HTN and chronic angina outpatient pathways.

ADULT DOSE (STANDARD)

PO START 2.5–5 mg daily; titrate gradually.

MAX DOSE

Common max 10 mg/day.

Route

PO once-daily long-acting profile

PEDIATRIC DOSE

Specialist pediatric HTN protocols.

Do not miss

Must-not-miss safety points

Major warning

- Edema is common and dose-limiting - Not a rate-control drug

Indications

USE IF: hypertension, chronic angina. AVOID IF: marked hypotension or severe edema intolerance.

Primary

  • Hypertension
  • Chronic stable angina

Secondary

  • Vasodilatory BP control pathways

Dosing

STANDARD (ADULT PO)

Slow outpatient titration favored.

ADULT DOSE

Typical start 2.5–5 mg daily, titrate to BP/symptoms.

PEDIATRIC DOSE

Specialist only.

MAX DOSE

Common max 10 mg/day.

Practical Note

Do not frame as urgent IV BP control medication.

Warnings

Clinical warnings

  • Vasodilatory adverse effects are expected (edema, flushing, headache, reflex symptoms).
  • Avoid rapid, uncontrolled BP drops from aggressive titration or inappropriate acute use.

Contraindications

  • Marked hypotension
  • Known severe hypersensitivity

Drug interactions

  • Additive hypotension with other antihypertensives
  • CYP3A4 interactions can alter CCB exposure and BP response
  • Additive hypotension with other antihypertensives.

Special populations

Pediatrics

Specialist pediatric HTN protocols.

Pregnancy

Pregnancy/

Lactation

use is protocol-driven by indication and specialist input.

Renal impairment

No major renal clearance barrier; monitor clinically.

Hepatic impairment

Slower titration may be needed in hepatic impairment.

Elderly

Lower starts reduce edema/hypotension burden.

Administration

PO daily at consistent time; avoid abrupt over-titration.

Monitoring

  • Monitor: - Monitor BP and hypotension symptoms (dizziness, near-syncope) - Monitor peripheral edema/flushing/headache trend after dose changes
  • Recheck: - Reassess response 1–2 weeks after titration
  • Hold if:
    - HOLD if severe symptomatic hypotension occurs

Overdose / toxicity

Clinical Picture

A) Mild β†’ dizziness, flushing, hypotension B) Moderate β†’ persistent vasodilatory hypotension, reflex symptoms, hyperglycemia trend C) Severe β†’ refractory shock

Immediate Actions

β€’ Airway + continuous monitoring (ABC, BP, telemetry) β€’ Hypotension β†’ IV fluids first-line β€’ Refractory hypotension β†’ early vasopressors β€’ Severe toxicity β†’ IV calcium + HIET + toxicology/ICU escalation β€’ Stop CCB immediately

Antidote

- No single antidote - CCB toxicity support β†’ IV calcium, vasopressors, HIET (protocol-guided) - Bradycardia / conduction compromise β†’ pacing when clinically indicated - Refractory severe toxicity β†’ ECMO consideration (center-dependent) - IV lipid β†’ selective toxicology-guided use

Decontamination

β€’ Recent oral ingestion β†’ activated charcoal if protected airway and early presentation (toxicology-guided)

Escalation

- Refractory shock / severe conduction toxicity β†’ ICU + toxicology - Persistent instability despite calcium + vasopressors β†’ HIET / pacing / ECMO pathway

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Amlodipine identity is chronic vasodilatory BP/angina control, not AV-node rate control.

Clinical pearls

Peripheral edema is usually dose-related vasodilatory edema, not automatically volume overload.

CCB safety

    Pharmacy Tool

    Preparation Calculator

    Amlodipine 1 mg/mL oral suspension

    suspension Β· oral

    Acknowledge the statements above to unlock volume scaling and ingredient quantities.

    Pharmacokinetics

    Long half-life supports once-daily chronic use.

    Mechanism of action

    DHP L-type calcium channel blockade with vascular smooth muscle predominance.

    Common brand names

    Saudi Arabia

    Norvasc, Amlodip, Amvasc

    Global

    (placeholder β€” verify local formulation)

    Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

    Country practice notes

    Global data (no country-specific data available)

    • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
    • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

    References

    Saudi Arabia

    • SFDA (Saudi Food & Drug Authority)
    • Saudi National Formulary / MOH (where available)

    International

    • WHO Model List of Essential Medicines (verify current edition)
    • US FDA or EU EMA product information (when national SmPC is unavailable)
    • ACC / AHA HTN/arrhythmia/HF guidance
    • ESC AF and chronic coronary syndrome guidance where relevant
    • FDA / SFDA product labeling

    Do not miss

    • Hypotension risk (especially over-aggressive titration / acute use errors)
    • Peripheral edema is common and dose-limiting
    • Short-acting nifedipine IR misuse for rapid BP lowering can be dangerous
    • Nifedipine pregnancy use is protocol-driven; avoid casual extrapolation